Novartis receives FDA approval of Xolair® (omalizumab) self-injection with prefilled syringe across all indications for appropriate patients

Novartis receives FDA approval of Xolair® (omalizumab) self-injection with prefilled syringe across all indications for appropriate patients

Apr 12, 2021
Source URL: https://www.novartis.com/us-en/news/media-releases/novartis-receives-fda-approval-xolair-omalizumab-self-injection-prefilled-syringe-across-all-indications-appropriate-patients-0

List of links present in page